Question 1

What is IDEXX Laboratories's P/FCF ratio?

Accepted Answer

IDEXX Laboratories (IDXX) P/FCF ratio is 40.7× as of July 22, 2026. The ratio is calculated by dividing market capitalisation by trailing twelve-month free cash flow, using USD-normalised financials (IAS 21 exchange-rate translation for non-USD reporters).

Question 2

How is the P/FCF ratio calculated?

Accepted Answer

P/FCF = Market Capitalisation ÷ Trailing Twelve-Month (TTM) Free Cash Flow, where Free Cash Flow = Operating Cash Flow − Capital Expenditures. All inputs are sourced from audited GAAP/IFRS filings and translated to USD using period-end exchange rates so the multiple is comparable across companies and currencies.

Question 3

What is the P/FCF ratio?

Accepted Answer

The price-to-free-cash-flow (P/FCF) ratio compares a company's market capitalisation to its trailing twelve-month (TTM) free cash flow. It is calculated as market cap ÷ TTM free cash flow, where free cash flow = operating cash flow − capital expenditures. Because FCF cannot be inflated by non-cash accounting items, P/FCF is often considered a cleaner measure of "earnings-power valuation" than P/E — especially for capital-intensive businesses where depreciation diverges from real cash outflows.

Question 4

What is a good P/FCF ratio for IDEXX Laboratories?

Accepted Answer

Mature companies that consistently convert profit into cash often trade at 15–25× P/FCF; capital-intensive businesses with lumpy capex typically trade lower. Compare against sector peers and against the company's own multi-year average — single-year P/FCF can be distorted by working-capital swings. For IDEXX Laboratories specifically, the relevant sector benchmark is the current sector median of 19.1×.

Question 5

Is IDEXX Laboratories's P/FCF ratio high or low?

Accepted Answer

IDEXX Laboratories's P/FCF ratio of 40.7× is below its own 5-year average of 62.5× and above the sector median of 19.1×. That places the current reading at the 1th percentile of its 10-year history. A higher multiple usually reflects stronger expected growth, lower perceived risk, or higher returns on capital; a lower multiple reflects the opposite.

Question 6

What is IDEXX Laboratories's historical P/FCF ratio range?

Accepted Answer

In the available daily series, IDEXX Laboratories (IDXX) P/FCF ratio has ranged from a low of 11.1× in 2002 to a high of 107.7× in 2023. The 5-year average is 62.5× and the 5-year median is 57.7×.

Question 7

What was IDEXX Laboratories's P/FCF ratio in 2025?

Accepted Answer

IDEXX Laboratories (IDXX) P/FCF ratio at the end of 2025 was 51.4×. Annual values reflect the multiple on the last trading day of each calendar year, using the trailing twelve-month free cash flow figure available at that date.

Question 8

Why does IDEXX Laboratories's P/FCF ratio change over time?

Accepted Answer

Valuation multiples move with two inputs: the numerator (market capitalisation, which tracks the share price) and the denominator (free cash flow). Share-price changes — driven by interest rates, earnings expectations, risk appetite, and broader market sentiment — typically dominate short-term moves, while changes in the underlying fundamental drive the longer-term trend. As a result, the ratio can rise during stock-price rallies even if the business itself has not become more valuable, and fall during sell-offs even when fundamentals are improving.


2025	$54.2B	$1.05B	51.4×	+9.0×	Dec 31, 2025
2024	$33.8B	$798M	42.4×	-17.3×	Dec 31, 2024
2023	$46.1B	$773M	59.7×	-26.2×	Dec 31, 2023
2022	$33.8B	$394M	85.8×	-2.0×	Dec 31, 2022
2021	$55.9B	$636M	87.8×	+8.8×	Dec 31, 2021
2020	$42.7B	$540M	79.1×	+5.3×	Dec 31, 2020
2019	$22.4B	$304M	73.8×	+15.8×	Dec 31, 2019
2018	$16.1B	$277M	58.0×	+11.9×	Dec 31, 2018
2017	$13.7B	$297M	46.1×	+7.3×	Dec 31, 2017
2016	$10.5B	$270M	38.8×	-10.8×	Dec 31, 2016
2015	$6.62B	$133M	49.6×	+9.2×	Dec 31, 2015
2014	$7.08B	$175M	40.4×	+7.4×	Dec 31, 2014
2013	$5.53B	$167M	33.0×	+2.0×	Dec 31, 2013
2012	$5.08B	$164M	31.0×	+5.6×	Dec 31, 2012
2011	$4.25B	$167M	25.4×	-3.1×	Dec 31, 2011
2010	$3.98B	$140M	28.5×	+1.7×	Dec 31, 2010
2009	$3.1B	$116M	26.8×	-21.0×	Dec 31, 2009
2008	$2.13B	$44.7M	47.8×	-3.2×	Dec 31, 2008
2007	$3.57B	$70M	51.0×	-13.2×	Dec 31, 2007
2006	$2.47B	$38.5M	64.2×	+39.4×	Dec 31, 2006
2005	$2.29B	$92.4M	24.8×	-3.5×	Dec 31, 2005
2004	$1.8B	$63.7M	28.3×	+12.2×	Dec 31, 2004
2003	$1.61B	$100M	16.0×	+3.6×	Dec 31, 2003
2002	$1.1B	$88.2M	12.5×	—	Dec 31, 2002


McKesson (MCK)	17.8×
Gilead Sciences (GILD)	16.9×
DexCom (DXCM)	16.9×
Pfizer (PFE)	16.7×
Humana (HUM)	16.4×
Quest Diagnostics (DGX)	16.3×
UnitedHealth Group (UNH)	15.9×
Labcorp Holdings (LH)	15.9×
Becton, Dickinson and (BDX)	14.0×
HCA Healthcare (HCA)	13.5×
Elevance Health (ELV)	13.4×
Incyte (INCY)	12.9×
CVS Health (CVS)	12.4×
Universal Health Services (UHS)	12.2×
Baxter International (BAX)	12.1×
Cardinal Health (CAH)	11.3×
IQVIA (IQV)	11.3×
Bristol-Myers Squibb (BMY)	10.4×
Biogen (BIIB)	10.3×
Zimmer Biomet Holdings (ZBH)	9.6×
Cigna (CI)	9.1×
Viatris (VTRS)	9.1×
DaVita (DVA)	6.9×
Teladoc Health (TDOC)	3.9×
Centene (CNC)	2.5×

P/FCF Ratio for IDEXX Laboratories (IDXX) 2002-2026

P/FCF Ratio daily chart for IDEXX Laboratories (IDXX)

Historical P/FCF Ratio for IDEXX Laboratories (IDXX) from 2002 to 2025

About P/FCF Ratio at IDEXX Laboratories (IDXX)

IDEXX Laboratories P/FCF Ratio by Year

IDEXX Laboratories P/FCF Ratio 2025: 51.4×

IDEXX Laboratories P/FCF Ratio 2024: 42.4×

IDEXX Laboratories P/FCF Ratio 2023: 59.7×

IDEXX Laboratories P/FCF Ratio 2022: 85.8×

IDEXX Laboratories P/FCF Ratio 2021: 87.8×

Sector peers by P/FCF Ratio — chart

Sector peers by P/FCF Ratio — table

Frequently asked questions

IDEXX Laboratories (IDXX) Key Financials